Improvement of Symptoms After Removal of the Essure® Contraceptive Implant
NCT ID: NCT06355713
Last Updated: 2025-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
444 participants
INTERVENTIONAL
2025-02-17
2037-02-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The physiopathological mechanism(s) is (are) not yet determined but several arguments are in favor of a dissemination of metallic elements contained in these implants whose accumulation could lead to inflammatory and/or allergic and/or autoimmune phenomena.
Carrying out a prospective study with long-term longitudinal follow-up appears essential to precisely assess the degree of improvement in the symptoms and quality of life of these patients, determine the most appropriate surgical techniques, and understand the pathophysiological mechanisms that may result in the implementation of specific treatments and relevant markers. From a surgical point of view, there is a real risk of fracture of implants whatever the type of intervention performed: study the biomechanical properties of implants with a view to characterizing their behavior to mechanical rupture but also their thermal resistance in an objective manner seems essential to limit the risk of fracture and help to inform the patient about the surgical technique proposed for explantation. From a biological point of view, the dosage of the metallic elements constituting ESSURE® implants and potentially toxic ones could make it possible to objectify the release of these metallic elements in the body. Analysis of pro-inflammatory cytokines, micro-RNAs (miRNA), quantitative analysis of inflammatory pathway messenger ribonucleic acid (mRNAs) (NanoString technology) and analysis of neuroinflammation by functional imaging should make it possible to explore potential pathophysiological mechanisms. This study responds to a significant request from patient associations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of ESSURE Devices Withdrawal on the Symptomatology of Patients
NCT03623126
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
NCT01948882
Pro-inflammatory Cytokines in Case of Essure®
NCT05944822
Observational Study on Contraception With Essure in France
NCT02510443
Use of Essure® Micro-inserts in Women With Hydrosalpinx Prior to In Vitro Fertilization: A Prospective, Multicenter, International Feasibility Study
NCT01221974
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Essure Group
Patients requiring removal of the Essure® contraceptive implant
Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination
An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.
The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.
At the end of the examination, the venous catheter will be removed and the visit will be over.
blood sample
Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).
Control patients : Blood sample pre-operatively (20 mL)
urine collection
Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).
Control patients : urine collection pre-operatively (10 mL)
Collection of a lock of hair
Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively
questionnaire
Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :
* PGI-I: symptom improvement score
* SF-12: quality of life with physical and mental dimension.
* FIQ: quality of life of women with fibromyalgia symptoms
* HADS: anxiety and depressive dimension
* MFI-20: fatigue according to 5 dimensions )
* VAS : pain assessment
* QDSA: assessment of sensory and emotional impact of pain
* FSFI : quality of sexual life
* Higham score
Control Group
Control patients who should benefit from a salpingectomy with or without hysterectomy for a benign indication
Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination
An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.
The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.
At the end of the examination, the venous catheter will be removed and the visit will be over.
blood sample
Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).
Control patients : Blood sample pre-operatively (20 mL)
urine collection
Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).
Control patients : urine collection pre-operatively (10 mL)
Collection of a lock of hair
Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively
questionnaire
Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :
* PGI-I: symptom improvement score
* SF-12: quality of life with physical and mental dimension.
* FIQ: quality of life of women with fibromyalgia symptoms
* HADS: anxiety and depressive dimension
* MFI-20: fatigue according to 5 dimensions )
* VAS : pain assessment
* QDSA: assessment of sensory and emotional impact of pain
* FSFI : quality of sexual life
* Higham score
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination
An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.
The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.
At the end of the examination, the venous catheter will be removed and the visit will be over.
blood sample
Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).
Control patients : Blood sample pre-operatively (20 mL)
urine collection
Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).
Control patients : urine collection pre-operatively (10 mL)
Collection of a lock of hair
Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively
questionnaire
Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :
* PGI-I: symptom improvement score
* SF-12: quality of life with physical and mental dimension.
* FIQ: quality of life of women with fibromyalgia symptoms
* HADS: anxiety and depressive dimension
* MFI-20: fatigue according to 5 dimensions )
* VAS : pain assessment
* QDSA: assessment of sensory and emotional impact of pain
* FSFI : quality of sexual life
* Higham score
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* woman aged 35 to 75
* patient with at least one Essure® implant
* surgical intervention planned because the patient is symptomatic: removal of the Essure® implant(s)
* planned intervention via vaginal route, laparoscopy, robotic surgery, or Transvaginal natural orifice transluminal endoscopic surgery (VNotes)
* patient having given free, informed and signed consent
Selection for MRI-PET examination:
* if the answer is "poor" or "bad" to the first question of the SF-12 pre-operatively
* no hysterectomy
* no analgesic treatment, or treatment stopped 48 hours before the examination
* no psychotropic treatment (anxiolytics, hypnotics (sleeping pills), antidepressants, mood stabilizers, neuroleptics)
* patient having given free, informed and signed consent
Control group:
* woman aged 35 to 75
* planned surgical intervention: salpingectomy with or without hysterectomy for benign indication
* planned intervention via vaginal route, laparoscopy, robotic surgery, or VNotes
* patient having given free, informed and signed consent
Selection for MRI-PET examination:
* age matching (+/- 5 years) with Essure® patients who have had an MRI-PET
* matching on surgical technique with Essure® patients who have had an MRI-PET: salpingectomy with or without hysterectomy
* no analgesic treatment, or treatment stopped 48 hours before the examination
* no psychotropic treatment (anxiolytics, hypnotics (sleeping pills), antidepressants, mood stabilizers, neuroleptics)
* patient having given free, informed and signed consent
Exclusion Criteria
* asymptomatic patient
* planned intervention by laparotomy
* patient potentially exposed to other heavy metals: wearer of metallic orthopedic equipment (hip or knee prosthesis, etc.), wearer of coronary stent, or tubal ligation clip
* inability to understand the information given
* persons deprived of liberty by a judicial or administrative decision
* people undergoing psychiatric care
* people admitted to a health or social establishment for purposes other than research
* adults subject to a legal protection measure (guardianship, curatorship)
* people not affiliated to a social security scheme or beneficiaries of a similar scheme
* person participating in another interventional research that may interfere with the research
Selection for MRI-PET examination:
* claustrophobia
* dosimetry of all radiological examinations over the past year not acceptable
Control Group :
* current pregnancy
* patient with cancer
* patient who has already had an Essure® implant removed
* patient potentially exposed to heavy metals: wearer of metallic orthopedic equipment (hip or knee prosthesis, etc.), wearer of coronary stent, or tubal ligation clip
* planned intervention by laparotomy
* inability to understand the information given
* persons deprived of liberty by a judicial or administrative decision
* people undergoing psychiatric care
* people admitted to a health or social establishment for purposes other than research
* adults subject to a legal protection measure (guardianship, curatorship)
* people not affiliated to a social security scheme or beneficiaries of a similar scheme
* person participating in another interventional research that may interfere with the research
Selection for MRI-PET examination:
* claustrophobia
* dosimetry of all radiological examinations over the past year not acceptable
35 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Angers
Angers, , France
Hôpital Femme Mère Enfant (Hospices Civils de Lyon)
Bron, , France
Hôpital Bicêtre
Le Kremlin-Bicêtre, , France
Hôpital Jeanne de Flandres
Lille, , France
Hôpital de La Conception
Marseille, , France
Institut Mère Enfant Alix de Champagne, CHU Reims
Reims, , France
CHU de Rouen
Rouen, , France
Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
Hôpital Paule de Viguier, CHU de Toulouse
Toulouse, , France
Hôpital André Mignot, Centre Hospitalier de Versailles
Versailles, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A02010-45
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL23_0899
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.